# JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

> clinical trial · VERIFIED · 2026-07-07

Status: RECRUITING · Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Condition: Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

- Company: Shanghai Junshi Bioscience Co., Ltd.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07518160

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.